AIMS/HYPOTHESIS: Adipokines may be important in mediating signals from adipocytes to insulin-sensitive tissue and vasculature. We studied the effect of different glucose-lowering therapies on serum levels of plasminogen activator inhibitor-1 (PAI-1), high-sensitivity C-reactive protein (hs-CRP), TNF-alpha, leptin, adiponectin and ghrelin in patients with type 2 diabetes. SUBJECTS AND METHODS: Twenty-eight patients with poorly controlled type 2 diabetes who were receiving oral hypoglycaemic agents were allocated to one of the following groups, and treated for 1 year: (1) lifestyle intervention (L); (2) insulin treatment (I); and (3) combined treatment (L+I). RESULTS: Similar improvements in glycaemic control occurred in all three groups. There was a reduction in body weight of 3.0 kg (median) (95% CI -5.9 to -2.0) in group L, whereas in groups L+I and I body weight increased by 3.5 kg (95% CI 1.5-4.9) and 4.9 kg (95% CI -3.1 to 8.2), respectively. By trend analyses, group L had reduced levels of PAI-1 (p=0.002), hs-CRP (p<0.0001) and TNF-alpha (p=0.006), while no significant changes were observed in the levels of leptin or adiponectin. In group I, the median levels of PAI-1 (p=0.008), TNF-alpha (p=0.058) and leptin (p=0.004) increased. In the L+I group there was a reduction in PAI-1 levels (p=0.014) and an increase in levels of leptin (p<0.001). The differences in changes in the levels of PAI-1, hs-CRP, TNF-alpha and leptin between groups were also significant (all p<0.01). CONCLUSIONS/ INTERPRETATION: Improvement of glycaemic control through lifestyle intervention in type 2 diabetes had more beneficial effects on adipokine levels than when the same lowering of HbA(1c) was achieved with insulin treatment.
RCT Entities:
AIMS/HYPOTHESIS: Adipokines may be important in mediating signals from adipocytes to insulin-sensitive tissue and vasculature. We studied the effect of different glucose-lowering therapies on serum levels of plasminogen activator inhibitor-1 (PAI-1), high-sensitivity C-reactive protein (hs-CRP), TNF-alpha, leptin, adiponectin and ghrelin in patients with type 2 diabetes. SUBJECTS AND METHODS: Twenty-eight patients with poorly controlled type 2 diabetes who were receiving oral hypoglycaemic agents were allocated to one of the following groups, and treated for 1 year: (1) lifestyle intervention (L); (2) insulin treatment (I); and (3) combined treatment (L+I). RESULTS: Similar improvements in glycaemic control occurred in all three groups. There was a reduction in body weight of 3.0 kg (median) (95% CI -5.9 to -2.0) in group L, whereas in groups L+I and I body weight increased by 3.5 kg (95% CI 1.5-4.9) and 4.9 kg (95% CI -3.1 to 8.2), respectively. By trend analyses, group L had reduced levels of PAI-1 (p=0.002), hs-CRP (p<0.0001) and TNF-alpha (p=0.006), while no significant changes were observed in the levels of leptin or adiponectin. In group I, the median levels of PAI-1 (p=0.008), TNF-alpha (p=0.058) and leptin (p=0.004) increased. In the L+I group there was a reduction in PAI-1 levels (p=0.014) and an increase in levels of leptin (p<0.001). The differences in changes in the levels of PAI-1, hs-CRP, TNF-alpha and leptin between groups were also significant (all p<0.01). CONCLUSIONS/ INTERPRETATION: Improvement of glycaemic control through lifestyle intervention in type 2 diabetes had more beneficial effects on adipokine levels than when the same lowering of HbA(1c) was achieved with insulin treatment.
Authors: S Adamopoulos; J Parissis; C Kroupis; M Georgiadis; D Karatzas; G Karavolias; K Koniavitou; A J Coats; D T Kremastinos Journal: Eur Heart J Date: 2001-05 Impact factor: 29.983
Authors: H Yki-Järvinen; L Ryysy; M Kauppila; E Kujansuu; J Lahti; T Marjanen; L Niskanen; S Rajala; S Salo; P Seppälä; T Tulokas; J Viikari; M R Taskinen Journal: J Clin Endocrinol Metab Date: 1997-12 Impact factor: 5.958
Authors: Anthony J G Hanley; Andreas Festa; Ralph B D'Agostino; Lynne E Wagenknecht; Peter J Savage; Russell P Tracy; Mohammed F Saad; Steven M Haffner Journal: Diabetes Date: 2004-07 Impact factor: 9.461
Authors: Anne M Wolf; Mark R Conaway; Jayne Q Crowther; Kristen Y Hazen; Jerry L Nadler; Beverly Oneida; Viktor E Bovbjerg Journal: Diabetes Care Date: 2004-07 Impact factor: 19.112
Authors: D E Laaksonen; L Niskanen; K Nyyssönen; K Punnonen; T-P Tuomainen; V-P Valkonen; R Salonen; J T Salonen Journal: Diabetologia Date: 2004-07-28 Impact factor: 10.122
Authors: J Yoon; S Subramanian; Y Ding; S Wang; L Goodspeed; B Sullivan; J Kim; K D O'Brien; A Chait Journal: Diabetologia Date: 2011-02-17 Impact factor: 10.122
Authors: L Maria Belalcazar; David M Reboussin; Steven M Haffner; Ron C Hoogeveen; Andrea M Kriska; Dawn C Schwenke; Russell P Tracy; F Xavier Pi-Sunyer; Christie M Ballantyne Journal: Diabetes Care Date: 2010-08-03 Impact factor: 19.112
Authors: P Matafome; E Nunes; T Louro; C Amaral; J Crisóstomo; L Rodrigues; A R Moedas; P Monteiro; A Cipriano; R Seiça Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2008-10-21 Impact factor: 3.000
Authors: Niki Katsiki; Dimitri P Mikhailidis; Anna Gotzamani-Psarrakou; Triantafillos P Didangelos; John G Yovos; Dimitrios T Karamitsos Journal: Open Cardiovasc Med J Date: 2011-06-20